Effects of rivaroxaban therapy on ROTEM coagulation parameters in patients with venous thromboembolism

Advances in Clinical and Experimental Medicine

Volumn 24, Issue 6, 2015, Pages 995-1000

  Chojnowski, Krzysztof ^a   Górski, Tomasz ^a   Robak, Marta ^a   Treliński, Jacek ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Anti FXa method; APTT; PT; ROTEM

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; FIBRINOGEN; RIVAROXABAN;

ANTICOAGULATION; ARTICLE; BLOOD CLOTTING PARAMETERS; BLOOD CLOTTING TEST; BLOOD CLOTTING TIME; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; HEMATOLOGY EQUIPMENT; HUMAN; OUTCOME ASSESSMENT; PARTIAL THROMBOPLASTIN TIME; PREDICTIVE VALUE; ROTATION THROMBOELASTOMETRY; SCREENING; SENSITIVITY AND SPECIFICITY; THROMBOELASTOGRAPHY; VENOUS THROMBOEMBOLISM; BLOOD; BLOOD CLOTTING; CASE CONTROL STUDY; DRUG EFFECTS; DRUG MONITORING; PROCEDURES; PROTHROMBIN TIME; TIME; TREATMENT OUTCOME;

BLOOD COAGULATION; CASE-CONTROL STUDIES; DRUG MONITORING; FACTOR XA INHIBITORS; HUMANS; PARTIAL THROMBOPLASTIN TIME; PREDICTIVE VALUE OF TESTS; PROTHROMBIN TIME; RIVAROXABAN; THROMBELASTOGRAPHY; TIME FACTORS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 84964695907     PISSN: 18995276     EISSN: 24512680     Source Type: Journal    
DOI: 10.17219/acem/42147     Document Type: Article

References (18)

1. Mueck W, Stampfuss J, Kubitza D, Becka M: Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet 2014, 53, 1-16.
2. Bayer Pharma AG: Xarelto (rivaroxaban) Summary of Product Characteristics; 2013. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000944/WC500057108.pdf (Accessed 14 March 2015).
3. Jannsen Pharmaceuticals Inc. Xarelto (rivaroxaban) Prescribing Informaton 2013. http://www.accesdata.fda.gov/ /drugsatda-docs/label/2013/022406s004lbl.pdf (Accessed 14 March 2015).
4. Samama MM: Which test to use to measure the anticoagulant effect of rivaroxaban: the anti-factor Xa assay. J Thromb Haemost 2013, 11, 579-580.
5. Lindhoff-Last E, Ansell J, Spiro T, Samama MM: Laboratory testing of rivaroxaban in routine clinical practice: when, how, and which assays. Ann Med 2013, 45, 423-429.
6. Vanassche T, Vandenbriele C, Peerlinck K, Verhamme P: Pharmacotherapy with oral Xa inhibitors for venous thromboembolism. Expert Opin Pharmacother 2015, 16, 645-658.
7. Theusinger OM, Nürnberg J, Asmis LM, Seifert B, Spahn DR: Rotation thromboelastometry (ROTEM) stability and reproducibility over time. Eur J Cardiothorac Surg 2010, 37, 677-683.
8. Müller MC, Meijers JC, Vroom MB, Juffermans NP: Utility of thromboelastography and/or thromboelastometry in adults with sepsis: a systematic review. Crit Care 2014, 18, 30.
9. Lang T, von Depka M: Possibilities and limitations of thrombelastometry/-graphy. Hamostaseologie 2006, 26, 20-29.
10. Treliński J, Misiewicz M, Robak M, Smolewski P, Chojnowski K: Assessment of rotation thromboelastometry (ROTEM) parameters in patients with multiple myeloma at diagnosis. Thromb Res 2014, 133, 667-670.
11. Luddington RJ: Thrombelastography/thromboelastometry. Clin Lab Haematol 2005, 27, 81-90.
12. Lang T, Bauters A, Braun SL, Pötzsch B, von Pape KW, Kolde HJ, Lakner M: Multi-centre investigation on reference ranges for ROTEM thromboelastometry. Blood Coagul Fibrinolysis 2005, 16, 301-310.
13. Kozek-Langenecker S: Management of massive operative blood loss. Minerva Anestesiol 2007, 73, 401-415.
14. Casutt M, Konrad C, Schuepfer G: Effect of rivaroxaban on blood coagulation using the viscoelastic coagulation test ROTEM™. Anaesthesist 2012, 61, 948-953.
15. Adelmann D, Wiegele M, Wohlgemuth RK, Koch S, Frantal S, Quehenberger P, Scharbert G, Kozek-Langenecker S, Schaden E: Measuring the activity of apixaban and rivaroxaban with rotational thrombelastometry. Thromb Res 2014, 134, 918-923.
16. Oswald E, Velik-Salchnera C, Innerhofera P, Taubera H, Auckenthalerb T, Ulmerc H, Streifd W: Results of rotational thromboelastometry, coagulation activation markers and thrombin generation assays in orthopedic patients during thromboprophylaxis with rivaroxaban and enoxaparin: a prospective cohort study. Blood Coagul Fibrinolysis 2015, 26, 136-144.
17. Barrett YC, Wang Z, Frost C, Shenker A: Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 2010, 104, 1263-1271.
18. Lindhoff-Last E, Samama MM, Ortel TL, Weitz JI, Spiro TE: Assays for measuring rivaroxaban: their suitability and limitations. Ther Drug Monit 2010, 32, 673-679.